G1028 HCPCS code: Take-home supply of nasal naloxone; 2-pack of 8mg per 0.1 ml nasal spray (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure
G1028 is the HCPCS Level II code for take-home supply of nasal naloxone; 2-pack of 8mg per 0.1 ml nasal spray (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure. In 2024 Medicare paid an average of $122.45 per service for G1028 across 649 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. Medicare volume rose 160% from 2023 to 2024 (250 to 649 services). In 2024, about 34 clinicians billed Medicare for G1028 for 225 beneficiaries.
Code details
| Field | Value |
|---|---|
| Section | G codes — Procedures and professional services (temporary) |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 11 — Priced using national relative value units (Physician Fee Schedule) |
| BETOS category | Z2 |
| Added | 2022-01-01 |
| Last action effective | 2022-01-01 |
Who bills G1028 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 34 |
| Medicare beneficiaries | 225 |
| States with claims | 4 |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for G1028, 2023–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2023 | 250 | 130 | $104.05 | $102.11 |
| 2024 | 649 | 225 | $123.04 | $122.45 |
States with the most G1028 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| California | 581 | $122.16 |
| Oregon | 28 | $125.18 |
| Maryland | 21 | $124.16 |
| Michigan | 18 | $125.31 |
Medicare policy articles for this code
- A59718: Billing and Coding: Opioid Treatment Programs (Palmetto GBA (MAC - Part A, MAC - Part B))
Covered diagnoses (39 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| F11.10 | Opioid abuse, uncomplicated | 1 |
| F11.11 | Opioid abuse, in remission | 1 |
| F11.120 | Opioid abuse with intoxication, uncomplicated | 1 |
| F11.121 | Opioid abuse with intoxication delirium | 1 |
| F11.122 | Opioid abuse with intoxication with perceptual disturbance | 1 |
| F11.13 | Opioid abuse with withdrawal | 1 |
| F11.14 | Opioid abuse with opioid-induced mood disorder | 1 |
| F11.150 | Opioid abuse with opioid-induced psychotic disorder with delusions | 1 |
| F11.151 | Opioid abuse with opioid-induced psychotic disorder with hallucinations | 1 |
| F11.181 | Opioid abuse with opioid-induced sexual dysfunction | 1 |
Showing 10 of 39. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for G1028
- 2022-01-01: G1028 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code G1028?
G1028 is the HCPCS Level II code for take-home supply of nasal naloxone; 2-pack of 8mg per 0.1 ml nasal spray (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure. Short descriptor: "Take home supply 8mg per 0.1".
How much does Medicare pay for G1028?
In 2024, the average Medicare payment was $122.45 per service (average allowed $123.04).
Does Medicare cover G1028?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for G1028?
Medicare policy articles that cite G1028 list 39 covered ICD-10-CM diagnosis codes across 1 article. The most cited include F11.10 (Opioid abuse, uncomplicated), F11.11 (Opioid abuse, in remission), F11.120 (Opioid abuse with intoxication, uncomplicated). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
Related G10 codes
- G1000 — Clinical decision support mechanism applied pathways, as defined by the medicare appropriate use criteria program
- G1001 — Clinical decision support mechanism evicore, as defined by the medicare appropriate use criteria program
- G1002 — Clinical decision support mechanism medcurrent, as defined by the medicare appropriate use criteria program
- G1003 — Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program
- G1004 — Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program
- G1005 — Clinical decision support mechanism national imaging associates, as defined by the medicare appropriate use criteria program
- G1006 — Clinical decision support mechanism test appropriate, as defined by the medicare appropriate use criteria program
- G1007 — Clinical decision support mechanism aim specialty health, as defined by the medicare appropriate use criteria program
- G1008 — Clinical decision support mechanism cranberry peak, as defined by the medicare appropriate use criteria program
- G1009 — Clinical decision support mechanism sage health management solutions, as defined by the medicare appropriate use criteria program
- G1010 — Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program
- G1011 — Clinical decision support mechanism, qualified tool not otherwise specified, as defined by the medicare appropriate use criteria program
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under G1028
- Watch G1028 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for G1028
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.